{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:38:14Z","timestamp":1791005894736,"version":"4.1.0"},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,12,1]]},"DOI":"10.2169\/internalmedicine.3028-23","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T18:09:58Z","timestamp":1713809398000},"page":"3209-3215","source":"Crossref","is-referenced-by-count":10,"title":["A Rare Case of Overlapping Durvalumab-induced Myositis, Takotsubo-like Morphological Changes Caused by Myocarditis, and Myasthenia Gravis"],"prefix":"10.2169","volume":"63","author":[{"given":"Shoichiro","family":"Saito","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Hontsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nara Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Hiraoka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nara Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nara Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nara Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nara Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Okuda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nara Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Sugie","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nara Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Muro","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nara Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Puzanov I, Diab A, Abdallah K, et al.; the Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5: 95, 2017.","DOI":"10.1186\/s40425-017-0300-z"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Huang YT, Chen YP, Lin WC, Su WC, Sun YT. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol 11: 634, 2020.","DOI":"10.3389\/fneur.2020.00634"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Rossi S, Gelsomino F, Rinaldi R, et al. Peripheral nervous system adverse events associated with immune checkpoint inhibitors. J Neurol 270: 2975-2986, 2023.","DOI":"10.1007\/s00415-023-11625-1"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89: 1127-1134, 2017.","DOI":"10.1212\/WNL.0000000000004359"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Mann JD, Johns TR, Campa JF. Long-term administration of corticosteroids in myasthenia gravis. Neurology 26: 729-740, 1976.","DOI":"10.1212\/WNL.26.8.729"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F. Myasthenia gravis: prolonged treatment with steroids. Neurology 34: 170-174, 1984.","DOI":"10.1212\/WNL.34.2.170"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 15: 291-298, 1984.","DOI":"10.1002\/ana.410150316"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Shalata W, Abu-Salman A, Steckbeck R, Mathew Jacob B, Massalha I, Yakobson A. Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review. Cancers 13: 5218, 2021.","DOI":"10.3390\/cancers13205218"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Arora P, Talamo L, Dillon P, et al. Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. Cardiooncology 6: 21, 2020.","DOI":"10.1186\/s40959-020-00076-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Soman B, Dias MC, Rizvi SAJ, Kardos A. Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment. BMJ Case Rep 15: e251966, 2022.","DOI":"10.1136\/bcr-2022-251966"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Longinow J, Zmaili M, Skoza W, et al. Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: a single-center case series. Cancer Med 12: 2281-2289, 2023.","DOI":"10.1002\/cam4.5050"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Cham J, Ng D, Nicholson L. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report. J Med Case Rep 15: 278, 2021.","DOI":"10.1186\/s13256-021-02858-7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lipe DN, Galvis-Carvajal E, Rajha E, Wechsler AH, Gaeta S. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome. Am J Emerg Med 46: 51-55, 2021.","DOI":"10.1016\/j.ajem.2021.03.005"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Dolladille C, Ederhy S, Allouche S, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer 8: e000261, 2020.","DOI":"10.1136\/jitc-2019-000261"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71: 1755-1764, 2018.","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Cheng K, Wang Y, Zhou Y, Xia R, Tang L, Liu J. Neurological adverse events induced by immune checkpoint inhibitors in non-small cell lung cancer: current perspectives and new development. Clin Med Insights Oncol 15: 11795549211056261, 2021.","DOI":"10.1177\/11795549211056261"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Utsugisawa K, Nagane Y, Akaishi T, et al. Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve 55: 794-801, 2017.","DOI":"10.1002\/mus.25397"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 62: 442-446, 2005.","DOI":"10.1001\/archneur.62.3.442"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Suzuki S, Utsugisawa K, Yoshikawa H, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 66: 1334-1338, 2009.","DOI":"10.1001\/archneurol.2009.229"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Suzuki S, Utsugisawa K, Nagane Y, Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011: 740583, 2011.","DOI":"10.4061\/2011\/740583"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kufukihara K, Watanabe Y, Inagaki T, et al. Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and\/or myocarditis. Sci Rep 9: 5284, 2019.","DOI":"10.1038\/s41598-019-41730-z"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Takamatsu K, Nakane S, Suzuki S, et al. Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia. Ann Clin Transl Neurol 5: 1421-1427, 2018.","DOI":"10.1002\/acn3.654"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sugimoto T, Ochi K, Ishikawa R, et al. Initial deterioration and intravenous methylprednisolone therapy in patients with myasthenia gravis. J Neurol Sci 412: 116740, 2020.","DOI":"10.1016\/j.jns.2020.116740"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. M\u00f6hn N, Beutel G, Gutzmer R, Ivanyi P, Satzger I, Skripuletz T. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook. J Clin Med 8: 1777, 2019.","DOI":"10.3390\/jcm8111777"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7: 319, 2019.","DOI":"10.1186\/s40425-019-0774-y"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Becquart O, Lacotte J, Malissart P, et al. Myasthenia gravis induced by immune checkpoint inhibitors. J Immunother 42: 309-312, 2019.","DOI":"10.1097\/CJI.0000000000000278"},{"key":"27","unstructured":"27. Brahmer JR, Lacchetti C, Schneider BJ, et al.; the National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36: 1714-1768, 2018."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/23\/63_3028-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T22:29:49Z","timestamp":1733524189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/23\/63_3028-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":27,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3028-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]},"article-number":"3028-23"}}